GlassScriptPhysician profile
Carolina Bernabe Ramirez
NPI 1538501838
$1,452.47
in general payments reported to CMS, 2019-2025
20 companies · $15.32 in 2025
The $15.32 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $49.49 · 2021: $20.49 · 2022: $777 · 2023: $26.66 · 2024: $429 · 2025: $15.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $362.21 | 2019-2024 | |
| Seagen INC. | $230.66 | 2022 | |
| Pfizer INC. | $173.81 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $147.06 | 2024 | |
| Novartis Pharmaceuticals Corporation | $105.72 | 2022 | |
| Rigel Pharmaceuticals, INC. | $71.04 | 2021-2022 | |
| Celgene Corporation | $54.65 | 2022 | |
| Genentech USA, INC. | $46.49 | 2024 | |
| Janssen Biotech, INC. | $42.57 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $34.98 | 2022 | |
| Deciphera Pharmaceuticals INC. | $26.66 | 2023 | Qinlock |
| Ardelyx, INC. | $22.17 | 2022 | |
| Global Blood Therapeutics, INC. | $22.01 | 2022 | |
| Taiho Oncology, INC. | $21.33 | 2024 | |
| Foundation Medicine, INC. | $21.13 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.52 | 2022 | |
| Genzyme Corporation | $15.35 | 2022 | |
| Stemline Therapeutics INC. | $15.32 | 2025 | Orserdu |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolina Bernabe Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.